The patient’s last bilirubin levels 2 days before G-CSF administration (hospital day 19) were 1.34 mg/dL (total), and 0.55 mg/dL (direct), and all liver function tests within normal limits (AST 7 U/L, ALT 13 U/L, ALP 67 U/L), reducing the likelihood that chemotherapy was responsible for the subsequent hyperbilirubinemia.[5] By the second day of G-CSF therapy (hospital day 23), the patient’s total bilirubin had begun to rise, reaching 3.08 mg/dL, with a direct bilirubin of 1.73 mg/dL. The gene discussed is CSF3; the disease is Hyperbilirubinemia.